Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73) for Treatment of Neurodevelopmental Disorders
January 08 2024 - 7:30AM
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:
AVXL), a clinical-stage biopharmaceutical company developing
differentiated therapeutics for the treatment of neurodegenerative
and neurodevelopmental disorders including Alzheimer’s disease,
Parkinson’s disease, Rett syndrome and other central nervous system
(CNS) disorders, announced today it was granted new U.S. Patent No.
11,839,600 entitled “NEURODEVELOPMENTAL DISORDER THERAPY” from the
United States Patent and Trademark Office (USPTO) for its patent
application number 17/890,083. Anavex’s newest patent expands
coverage of ANAVEX®2-73 (blarcamesine) therapy to ameliorate
various conditions associated with loss-of-function mutations of
the gene encoding methyl-CpG binding protein (MeCP2).
The patent claims protect use of ANAVEX®2-73
(blarcamesine) to address a range of symptoms exhibited by patients
suffering from neurodevelopmental and neurological conditions
related to McCP2, such as abnormal breathing, abnormal cardiac
function, abnormal feeding, abnormal choking, weight gain failure,
abnormal sleep, seizures, abnormal gadolinium-enhancing lesions.
Such conditions are frequently associated with diseases such as
Rett syndrome, autism spectrum disorder, multiple sclerosis,
cerebral palsy, Angelman syndrome, Williams syndrome, pervasive
developmental disorder not otherwise specified (PDD-NOS), childhood
disintegrative disorder, Smith-Magenis syndrome, non-syndromic
mental retardation, idiopathic neonatal encephalopathy, and
idiopathic cerebral palsy. This newest patent is expected to remain
in force at least until January 2037, not including any patent term
extension.
“This new patent on use of ANAVEX®2-73
(blarcamesine) in ameliorating difficult symptoms associated with
loss-of-function gene mutations of MeCP2 will be important for
Anavex, further reinforcing our already strong position providing
novel and effective therapies for debilitating neurodevelopmental
and neurological diseases,” said Christopher U. Missling, PhD,
President and Chief Executive Officer of Anavex. He further added:
“We are pleased with the continued development of the patent
portfolio for ANAVEX®2-73 (blarcamesine). The grant of this new
patent to Anavex further demonstrates our strong overall commitment
to protecting the innovation and commercial opportunity of our
product portfolio.”
About Neurodevelopmental
Disorders
Neurodevelopmental disorders refer to a group of
conditions that affect the way the brain and nervous system
develop. These disorders can cause changes to thinking, feeling,
language, and physical abilities like movement and coordination.
Neurodevelopmental conditions typically start before adulthood and
may continue into adulthood. They are often associated with social
impairments and difficulties in communication.1 The number of
people globally with developmental intellectual disability was
estimated at 107.62 million according to IHME, Global Burden of
Disease (2019).2
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a
publicly traded biopharmaceutical company dedicated to the
development of novel therapeutics for the treatment of
neurodegenerative and neurodevelopmental disorders, including
Alzheimer's disease, Parkinson's disease, Rett syndrome, and other
central nervous system (CNS) diseases, pain, and various types of
cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine),
has successfully completed a Phase 2a and a Phase 2b/3 clinical
trial for Alzheimer's disease, a Phase 2 proof-of-concept study in
Parkinson's disease dementia, and both a Phase 2 and a Phase 3
study in adult patients with Rett syndrome. ANAVEX®2-73 is an
orally available drug candidate that restores cellular homeostasis
by targeting sigma-1 and muscarinic receptors. Preclinical studies
demonstrated its potential to halt and/or reverse the course of
Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant,
anti-amnesic, neuroprotective, and anti-depressant properties in
animal models, indicating its potential to treat additional CNS
disorders, including epilepsy. The Michael J. Fox Foundation for
Parkinson's Research previously awarded Anavex a research grant,
which fully funded a preclinical study to develop ANAVEX®2-73 for
the treatment of Parkinson's disease. ANAVEX®3-71, which targets
sigma-1 and M1 muscarinic receptors, is a promising clinical stage
drug candidate demonstrating disease-modifying activity against the
major hallmarks of Alzheimer's disease in transgenic (3xTg-AD)
mice, including cognitive deficits, amyloid, and tau pathologies.
In preclinical trials, ANAVEX®3-71 has shown beneficial effects on
mitochondrial dysfunction and neuroinflammation. Further
information is available at www.anavex.com. You can also connect
with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not
strictly historical in nature are forward-looking statements. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties.
Actual events or results may differ materially from those projected
in any of such statements due to various factors, including the
risks set forth in the Company’s most recent Annual Report on Form
10-K filed with the SEC. Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. All forward-looking statements are qualified in
their entirety by this cautionary statement and Anavex Life
Sciences Corp. undertakes no obligation to revise or update this
press release to reflect events or circumstances after the date
hereof.
For Further Information:Anavex
Life Sciences Corp.Research & Business DevelopmentToll-free:
1-844-689-3939Email: info@anavex.com
Investors:Andrew J.
BarwickiInvestor Relations
Tel: 516-662-9461Email: andrew@barwicki.com
1
https://www.empowerbh.com/blog/what-are-neurodevelopmental-disorders/2
https://ourworldindata.org/neurodevelopmental-disorders
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From Apr 2024 to May 2024
Anavex Life Sciences (NASDAQ:AVXL)
Historical Stock Chart
From May 2023 to May 2024